Total Payments
$423,962
2024 Payments
$3,598
Companies
28
Transactions
264
Medicare Patients
395
Medicare Billing
$97,110
Payment Breakdown by Category
Research$418,601 (98.7%)
Food & Beverage$4,402 (1.0%)
Travel$905.37 (0.2%)
Education$53.47 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $418,601 | 76 | 98.7% |
| Food and Beverage | $4,402 | 183 | 1.0% |
| Travel and Lodging | $905.37 | 2 | 0.2% |
| Education | $53.47 | 3 | 0.0% |
Payments by Type
Research
$418,601
76 transactions
General
$5,361
188 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $194,284 | 24 | $0 (2018) |
| Arbor Pharmaceuticals, Inc. | $155,732 | 8 | $0 (2019) |
| PFIZER INC. | $59,612 | 14 | $0 (2023) |
| Supernus Pharmaceuticals, Inc. | $3,583 | 17 | $0 (2019) |
| Eli Lilly and Company | $3,059 | 3 | $0 (2024) |
| Allergan, Inc. | $2,524 | 16 | $0 (2020) |
| F. Hoffmann-La Roche AG | $1,564 | 3 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $1,157 | 63 | $0 (2024) |
| Alkermes, Inc. | $467.59 | 30 | $0 (2024) |
| Sage Therapeutics, Inc. | $325.00 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,598 | 25 | Eli Lilly and Company ($2,950) |
| 2023 | $60,239 | 34 | PFIZER INC. ($59,612) |
| 2022 | $399.89 | 22 | Janssen Pharmaceuticals, Inc ($105.77) |
| 2021 | $551.28 | 27 | AbbVie Inc. ($107.11) |
| 2020 | $163.49 | 9 | Alkermes, Inc. ($52.61) |
| 2019 | $157,505 | 35 | Arbor Pharmaceuticals, Inc. ($155,732) |
| 2018 | $75,032 | 44 | ACADIA Pharmaceuticals Inc ($74,034) |
| 2017 | $126,475 | 68 | ACADIA Pharmaceuticals Inc ($120,250) |
All Payment Transactions
264 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $29.62 | General |
| Category: Neuroscience | ||||||
| 12/10/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: CNS | ||||||
| 10/23/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Neurology | ||||||
| 10/16/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Neuroscience | ||||||
| 10/15/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,872.00 | Research |
| Study: A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | ||||||
| 09/18/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Neuroscience | ||||||
| 08/21/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $32.10 | General |
| Category: Neuroscience | ||||||
| 08/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: NEUROSCIENCE | ||||||
| 08/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.66 | General |
| Category: PSYCHIATRY | ||||||
| 07/30/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: CNS | ||||||
| 07/24/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $35.16 | General |
| Category: Neuroscience | ||||||
| 07/17/2024 | Eli Lilly and Company | — | — | In-kind items and services | $77.66 | Research |
| Study: A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | ||||||
| 06/19/2024 | Janssen Pharmaceuticals, Inc | INVEGA TRINZA (Drug), INVEGA SUSTENNA | Food and Beverage | In-kind items and services | $29.70 | General |
| Category: Neuroscience | ||||||
| 06/04/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $113.88 | General |
| Category: Neuroscience | ||||||
| 05/13/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: Neuroscience | ||||||
| 05/01/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $28.97 | General |
| Category: Neuroscience | ||||||
| 04/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: NEUROSCIENCE | ||||||
| 03/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.22 | General |
| Category: NEUROSCIENCE | ||||||
| 03/20/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: Neuroscience | ||||||
| 03/06/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: CNS | ||||||
| 02/20/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $45.70 | General |
| Category: Neuroscience | ||||||
| 02/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: PSYCHIATRY | ||||||
| 02/06/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: Neuroscience | ||||||
| 01/23/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $31.53 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-042 | ACADIA Pharmaceuticals Inc | $194,170 | 23 |
| Adult Attention Deficit Hyperactivity Disorder ADHD Study With Amphetamine Sulfate | Arbor Pharmaceuticals, Inc. | $155,732 | 8 |
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $37,820 | 8 |
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $11,465 | 4 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $10,326 | 2 |
| A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | Eli Lilly and Company | $2,950 | 2 |
| Evaluation of SPN-812 ER 100 and 200 mg Efficacy and Safety in Children with ADHD - A Double-Blind, Placebo- Controlled, Pivotal Trial | Supernus Pharmaceuticals, Inc. | $2,139 | 5 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP FLEXIBLE-DOSE STUDY OF THE EFFICACY AND SAFETY OF SPN-812 IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | Supernus Pharmaceuticals, Inc. | $1,445 | 12 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $1,396 | 3 |
| Phase IIA US POP w SOD 3125-201-002 | Allergan Inc. | $693.11 | 7 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $356.00 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-2 STUDY | Eli Lilly and Company | $109.05 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 98 | 554 | $55,030 | $24,615 |
| 2022 | 2 | 96 | 593 | $50,725 | $24,056 |
| 2021 | 2 | 95 | 575 | $139,933 | $24,051 |
| 2020 | 2 | 106 | 600 | $51,525 | $24,387 |
Total Patients
395
Total Services
2,322
Medicare Billing
$97,110
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 43 | 255 | $31,875 | $12,233 | 38.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 44 | 277 | $18,975 | $10,957 | 57.7% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 11 | 22 | $4,180 | $1,425 | 34.1% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 47 | 281 | $35,125 | $13,627 | 38.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 49 | 312 | $15,600 | $10,430 | 66.9% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 47 | 272 | $34,000 | $13,788 | 40.6% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 48 | 303 | $105,933 | $10,263 | 9.7% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 52 | 287 | $35,875 | $14,670 | 40.9% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 54 | 313 | $15,650 | $9,718 | 62.1% |
About Dr. Michael Downing, MD
Dr. Michael Downing, MD is a Psychiatry healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639159346.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Downing, MD has received a total of $423,962 in payments from pharmaceutical and medical device companies, with $3,598 received in 2024. These payments were reported across 264 transactions from 28 companies. The most common payment nature is "" ($418,601).
As a Medicare-enrolled provider, Downing has provided services to 395 Medicare beneficiaries, totaling 2,322 services with total Medicare billing of $97,110. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Dallas, TX
- Active Since 01/19/2006
- Last Updated 11/12/2024
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1639159346
Products in Payments
- NUPLAZID (Drug) $194,284
- AR19 (Drug) $155,732
- NURTEC ODT (Drug) $49,285
- ZAVZPRET (Drug) $10,326
- Non-Covered Product (Drug) $1,564
- INVEGA SUSTENNA (Drug) $663.19
- VRAYLAR (Drug) $332.91
- ARISTADA (Drug) $291.56
- INVEGA TRINZA (Drug) $234.80
- Aristada 441 mg (Drug) $176.03
- CAPLYTA (Drug) $169.46
- INGREZZA (Drug) $152.75
- REXULTI (Drug) $137.67
- HETLIOZ (Drug) $125.03
- PERSERIS (Drug) $109.15
- AUSTEDO (Drug) $105.68
- LATUDA (Drug) $89.16
- NUEDEXTA (Drug) $70.55
- TRINTELLIX (Drug) $70.02
- UZEDY (Drug) $62.85
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Dallas
Dr. Darin Okuda, M.d, M.D
Psychiatry — Payments: $739,134
Psychiatry $739,134
Augustus Rush, Md, MD
Psychiatry — Payments: $737,518
Psychiatry $737,518
Dr. Mary Knesevich, M.d, M.D
Psychiatry — Payments: $634,383
Psychiatry $634,383
Dr. Stephen Vobach, M.d, M.D
Psychiatry — Payments: $314,024
Psychiatry $314,024
Madhukar Trivedi, Md, MD
Psychiatry — Payments: $264,753
Psychiatry $264,753
Dr. Scott Bartley, M.d, M.D
Psychiatry — Payments: $242,001
Psychiatry $242,001